特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性免疫不全症 (PID) : パイプライン分析

Primary Immune Deficiency (PID) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 229789
出版日 ページ情報 英文 125 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
原発性免疫不全症 (PID) : パイプライン分析 Primary Immune Deficiency (PID) - Pipeline Review, H1 2020
出版日: 2020年02月28日 ページ情報: 英文 125 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

原発性免疫不全症 (PID)は、弱まった免疫機構と定義されており、繰り返し感染症を引き起こし、その他の健康障害も発生しやすくなります。症候は、血液感染症、肺炎、気管支炎、副鼻腔感染症、耳感染症、髄膜炎、皮膚感染症、けいれん、食欲不振、吐き気や下痢などの消化器官障害があります。

当レポートでは、原発性免疫不全症 (PID)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

原発性免疫不全症 (PID) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Genethon
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • ProMetic Life Sciences Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (immune globulin (human) + hyaluronidase (recombinant))
  • GC-1112
  • Gene Therapy for Severe Combined Immune Deficiency
  • Gene Therapy for X-Linked SCID
  • Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency
  • GSK-2696273
  • immune globulin (human)
  • immune globulin (human)
  • OT-81
  • plerixafor
  • RI-002
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Primary Immune Deficiency (PID), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by AlloVir Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Emendo Biotherapeutics, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Enzyvant Sciences Ltd, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by GC Pharma, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Grifols SA, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Rocket Pharmaceuticals Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H1 2020
  • Primary Immune Deficiency (PID) - Dormant Projects, H1 2020
  • Primary Immune Deficiency (PID) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Primary Immune Deficiency (PID), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC11957IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2020, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 9, 3, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 9, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Primary Immune Deficiency (PID) - Overview
  • Primary Immune Deficiency (PID) - Therapeutics Development
  • Primary Immune Deficiency (PID) - Therapeutics Assessment
  • Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
  • Primary Immune Deficiency (PID) - Drug Profiles
  • Primary Immune Deficiency (PID) - Dormant Projects
  • Primary Immune Deficiency (PID) - Discontinued Products
  • Primary Immune Deficiency (PID) - Product Development Milestones
  • Appendix